An observational study in Periodontal Diseases, Periodontitis and Gingivitis; Chronic, sponsored by Ömer Faruk Okumuş. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Ömer Faruk Okumuş · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Periodontal Diseases with a site in Turkey — 25 open to participants now, 34 under way, none of them phase 3. Periodontal Diseases · Turkey.
Among the 160 studies in Periodontal Diseases with a site in Turkey, this one is the 20th largest by planned enrollment of the 91 observational ones that give a count, is one of 25 that started in 2025, is one of 91 observational ones, reaches primary completion later than 22 of the 33 other live ones, and was the 108th registered.
871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.
Browse Periodontal Diseases studies →25 of the 160 studies in Periodontal Diseases with a site in Turkey are open now. Recruiting first, the newest first:
Biruni University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Recep Tayyip Erdogan University Training and Research Hospital · Sites in Turkey
Ages 18–65 · Healthy volunteers
Recep Tayyip Erdogan University Training and Research Hospital · Sites in Turkey
Ages 18–70 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 100 across 304 observational studies indexed under Periodontal Diseases.
Median enrollment 60 across the 69 interventional studies, 88 across the 91 observational. Of the 123 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 160 have an industry lead sponsor. The 10 most frequent:
Ömer Faruk Okumuş is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Ömer Faruk Okumuş has 2 studies filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Periodontal Diseases with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07312045Ömer Faruk OkumuşHALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy | 2026-11-25 |
| NCT07887204Istanbul UniversityAntibiotic Resistance Genes in Periodontitis | 2026-12 |
| NCT07146776Saglik Bilimleri UniversitesiTreatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts | 2026-12-01 |
| NCT07802249Ravan MammadovPeriodontal Health in Adults Treated With Fixed Orthodontic Appliances or Clear Aligners | 2026-12-25 |
| NCT07944911Ordu UniversityChanges in Taurine Levels After Non-Surgical Periodontal Treatment and Their Association With Inflammatory and Apoptosis Marker | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 160 studies in Periodontal Diseases with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational clinical study aims to investigate the relationship between the HALP score (Hemoglobin × Albumin × Lymphocyte / Platelet), several blood-based inflammatory indices (including NLR, PLR, LMR, and SII), and salivary MMP-8 levels in individuals with periodontal health, gingivitis, and stage III/IV periodontitis. The study also evaluates how these biomarkers relate to healing following non-surgical periodontal therapy.
A total of 180 participants aged 18-65 years will be included: 50 healthy individuals, 50 patients with gingivitis, and 80 patients with stage III/IV periodontitis. All participants will undergo periodontal clinical examination and provide blood and saliva samples at baseline. Individuals in the gingivitis and periodontitis groups will receive standard non-surgical periodontal treatment (full-mouth debridement) and will return for a 3-month follow-up visit, where periodontal measurements will be repeated. In the periodontitis group, an additional blood sample will be collected at the 3-month follow-up visit.
The primary objective is to determine whether baseline HALP score, systemic inflammatory indices, and salivary MMP-8 levels differ between participants who show good versus poor healing after treatment. Secondary objective include comparing biomarker levels across periodontal status groups. The findings may contribute to early prediction of treatment response and personalized periodontal care.
Following baseline assessments, participants in the gingivitis and periodontitis groups will receive standard non-surgical periodontal therapy. Periodontal clinical measurements will be repeated at the 3-month follow-up visit in these groups. In accordance with the existing ethics committee approval and following further feasibility assessment, an additional blood sample will be collected at the 3-month follow-up visit exclusively from participants in the periodontitis group.
Adult individuals aged 18-65 years presenting to the periodontology clinic for routine examination or periodontal treatment. Participants will be assigned to healthy, gingivitis, or stage III/IV periodontitis groups based on periodontal diagnosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with no clinical signs of gingival inflammation, probing depth ≤3 mm, no clinical attachment loss, and no radiographic bone loss. These individuals serve as the healthy control group.
Procedure: Non-surgical Periodontal Therapy
Participants with visible signs of gingival inflammation and bleeding on probing, but without clinical attachment loss or radiographic bone loss. These individuals will receive standard non-surgical periodontal therapy.
Procedure: Non-surgical Periodontal Therapy
Participants diagnosed with stage III or stage IV periodontitis, characterized by clinical attachment loss, probing depth ≥5 mm, and radiographic bone loss. These individuals will receive standard non-surgical periodontal therapy and will be re-evaluated at 3 months.
Procedure: Non-surgical Periodontal Therapy
Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.
Differences in Baseline HALP Score Between Good and Poor Treatment Responders
Evaluation of whether baseline HALP score differs between good responders (\>2 mm reduction in probing depth at sites ≥5 mm) and poor responders (≤2 mm reduction) following non-surgical periodontal therapy in periodontitis patients.
Time frame: Baseline (T0) to 3 months after treatment (T2)
Differences in Baseline NLR Between Good and Poor Responders
Comparison of baseline neutrophil-to-lymphocyte ratio between good and poor responders in the periodontitis group.
Time frame: Baseline (T0)
Differences in Baseline PLR Between Good and Poor Responders
Comparison of baseline platelet-to-lymphocyte ratio between good and poor responders in the periodontitis group.
Time frame: Baseline (T0)
Differences in Baseline LMR Between Good and Poor Responders
Comparison of baseline lymphocyte-to-monocyte ratio between good and poor responders in the periodontitis group.
Time frame: Baseline (T0)
Differences in Baseline SII Between Good and Poor Responders
Comparison of baseline systemic immune-inflammation index between good and poor responders in the periodontitis group.
Time frame: Baseline (T0)
Differences in Baseline Salivary MMP-8 Between Good and Poor Responders
Comparison of baseline salivary MMP-8 levels between good and poor responders in the periodontitis group.
Time frame: Baseline (T0)
Baseline HALP Score Differences Across Periodontal Status Groups
Comparison of HALP score among healthy, gingivitis, and stage III/IV periodontitis groups.
Time frame: Baseline (T0)
Baseline NLR Differences Across Periodontal Status Groups
Comparison of neutrophil-to-lymphocyte ratio among the three periodontal groups.
Time frame: Baseline (T0)
Baseline PLR Differences Across Periodontal Status Groups
Comparison of platelet-to-lymphocyte ratio among the three periodontal groups.
Time frame: Baseline (T0)
Baseline LMR Differences Across Periodontal Status Groups
Comparison of lymphocyte-to-monocyte ratio among the three periodontal groups.
Time frame: Baseline (T0)
Baseline SII Differences Across Periodontal Status Groups
Comparison of systemic immune-inflammation index among the three periodontal groups.
Time frame: Baseline (T0)
Baseline Salivary MMP-8 Differences Across Periodontal Status Groups
Comparison of salivary MMP-8 among healthy, gingivitis, and periodontitis groups.
Time frame: Baseline (T0)
Changes in Probing Depth After Non-Surgical Periodontal Therapy
Mean reduction in probing depth from baseline to 3 months in gingivitis and periodontitis patients.
Time frame: Baseline (T0) to 3 months (T2)
Change in HALP Score After Non-Surgical Periodontal Therapy in Periodontitis Patients
Evaluation of the change in HALP score from baseline to 3 months after non-surgical periodontal therapy in patients with stage III/IV periodontitis.
Time frame: Baseline (T0) to 3 months (T2)
Correlations Between Clinical Periodontal Parameters and Biomarker Levels
Assessment of correlations between probing depth, bleeding on probing, plaque index, clinical attachment level, and biomarkers including HALP score, NLR, PLR, LMR, SII, and salivary MMP-8.
Time frame: Baseline (T0)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
Of 79 non-industry observational studies under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is close to that.
Counting every sponsor, half of 83 studies reached it within 13 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ömer Faruk Okumuş